Recently Viewed
Clear AllQuality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Bidding Date
26-Aug-2025 to
29-Aug-2025
Issue Size
₹121.03 Cr
Price Band
₹86 to ₹91
Allotment date
01-Sep-2025
Listing date
03-Sep-2025
Lot size
164
No. of shares
1,33,00,000
Fresh issue/OFS
₹121.03 Cr /--
Anlon Healthcare Ltd is a specialized chemical manufacturer engaged in producing high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs) that serve as critical raw materials for finished dosage formulations such as tablets, capsules, ointments, and syrups. Its portfolio also extends to nutraceutical APIs, personal care ingredients, and veterinary APIs, catering to diverse healthcare and wellness applications. With over 65 commercialized products and many more in development, the company focuses on anti-inflammatory, analgesic, antihistamine, antidepressant, anticoagulant, and nutritional segments. It also undertakes custom manufacturing of complex compounds, regulatory filings like Drug Master Files, and exports products meeting global pharmacopeia standards, reinforcing its role in supporting pharmaceutical innovation worldwide.
Category
Status
QIBs
1.1x
NIIs
10.6x
Retail
47.2x
Others
--
Total
7.1x
The issue size of Anlon Healthcare is ₹121.03 Cr.
Anlon Healthcare falls into Pharmaceuticals industry.
The Anlon Healthcare IPO will be listed on both NSE and BSE.
The open and close dates for the Anlon Healthcare are 26-Aug-2025 & 29-Aug-2025.
The price band for the Anlon Healthcare ipo is ₹86 to ₹91
The listing date of Anlon Healthcare IPO is 03-Sep-2025.
The purpose of this IPO is to raise fresh capital.
Anlon Healthcare total subscription ratio is 7.1X.
Key financial of the Anlon Healthcare are:
| Anlon Healthcare | FY-25 | FY-24 | FY-23 |
|---|---|---|---|
| Revenue (₹ Cr) | 120.29 | 66.58 | 112.88 |
| EBIT (₹ Cr) | 30.78 | 13.82 | 10.68 |
| Proft after Tax (₹ Cr) | 20.52 | 9.66 | 5.82 |
| Debt (₹ Cr) | 66.55 | 81.25 | 70.32 |
| Net Worth (₹ Cr) | 80.42 | 21.03 | 7.37 |
| RoE (%) | 25.51 | 45.92 | 78.92 |